Építés alatt – nem éles oldal
Belépés
Toborzás még nem indult4. fázis

Reduced-Dose Versus Full-Dose Alteplase for High-Risk Pulmonary Embolism

A legfontosabb adatok

Ki végzi
Sahlgrenska University Hospital
Hol
Dánia, Norvégia és Svédország22 helyszín, 3 országbanVálassz országot a helyszínekhez
Állapot
Toborzás még nem indult
Fázis
4. fázis
Résztvevők
400 fő, tervezett
Kezdés
2026. dec. 1.
Várható befejezés
2031. jan. 31.
A vizsgálat típusa
Beavatkozással járó, 2 csoportAz egyik csoport egy már használt kezelést kap, összehasonlításként.
A vizsgált kezelések
  • Reduced-dose alteplase
  • Full-dose alteplase
A regiszteradat frissítve
2026. október 28.

Ki vehet részt

Életkor
18 év felett
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 12 feltétel megnézéseKevesebb

Ki vehet részt

  • Participant aged 18 years or older
  • Acute pulmonary embolism verified by computed tomography pulmonary angiography or pulmonary angiography. In hemodynamically unstable participants unable to undergo immediate imaging, presumed pulmonary embolism may be diagnosed based on bedside echocardiographic findings consistent with acute right ventricular pressure overload and high clinical suspicion of pulmonary embolism, provided that alternative causes of hemodynamic instability have been reasonably excluded. In such cases, the treating clinician must have independently decided to initiate thrombolytic therapy irrespective of study participation, and confirmatory imaging demonstrating pulmonary embolism must be performed as soon as clinically feasible
  • High risk for early death, defined by at least one of the following:; High-risk pulmonary embolism according to European Society of Cardiology criteria:; Cardiac arrest with return of spontaneous circulation; Obstructive shock, defined as systolic blood pressure <90 mmHg or use of vasopressors to maintain systolic blood pressure ≥90 mmHg despite adequate filling status, together with end-organ hypoperfusion such as elevated serum lactate >2 mmol/L, altered mental status, or cold clammy skin; Persistent hypotension, defined as systolic blood pressure <90 mmHg or a drop in systolic blood pressure ≥40 mmHg for longer than 15 minutes, not caused by new-onset arrhythmia, hypovolemia, or sepsis; Abnormal right ventricular function on echocardiography or computed tomography pulmonary angiography, defined as right ventricular/left ventricular ratio ≥1.0, and elevated cardiac troponin above the local upper reference limit, and acute respiratory failure not primarily caused by underlying lung disease, defined as requiring facemask oxygen supplementation ≥12 L/min, high-flow nasal oxygen, or non-invasive ventilation with FiO2 ≥60% to reach oxygen saturation ≥94%
  • Female participants of childbearing potential must have a negative urine or serum pregnancy test

Ki nem vehet részt

  • Contraindication to systemic thrombolysis with one or more of the following:; History of hemorrhagic stroke; Ischemic stroke within the previous 6 months; Central nervous system neoplasm; Major trauma, major surgery, or major head injury within the previous 3 weeks; Active life-threatening bleeding, bleeding into a critical organ or area, or known severe bleeding diathesis; Chronic use of full-dose oral or parenteral anticoagulation before presentation
  • The participant has already received reperfusion treatment for the index pulmonary embolism before randomization, including systemic thrombolysis, surgical embolectomy, or catheter-directed intervention
  • Catastrophic pulmonary embolism, defined as ongoing cardiac arrest and/or need for extracorporeal cardiopulmonary resuscitation and/or immediate VA-ECMO as judged by the treating physicians
  • Known hypersensitivity to alteplase or any of its excipients
  • Any other condition that would put the participant at unacceptable risk from the trial interventions as judged by the treating clinician
  • Pregnancy
  • Current participation in another study that would interfere with participation in this trial
  • In countries where required by national regulations: lack of affiliation to a social security system or equivalent health insurance coverage

Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.

3 országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

High-risk pulmonary embolism is a life-threatening condition requiring immediate reperfusion therapy. Full-dose systemic thrombolysis is recommended as first-line treatment, but its use is limited by the risk of major bleeding, including intracranial hemorrhage. Reduced-dose systemic thrombolysis may reduce bleeding while maintaining clinical efficacy, but this strategy has not been adequately evaluated in patients with high-risk pulmonary embolism.

A teljes eredeti leírásKevesebb

REDSTEM is an international, multicenter, randomized, adaptive, open-label, blinded-endpoint phase 4 trial comparing reduced-dose alteplase with standard full-dose alteplase in adults with acute high-risk pulmonary embolism. The trial will assess whether reduced-dose alteplase preserves early clinical efficacy while reducing severe clinically significant bleeding. Participants will be followed for up to 12 months.

A vizsgálat 2 csoportja

  • Reduced-Dose AlteplaseA vizsgált kezelés

    Participants randomized to reduced-dose systemic thrombolysis will receive alteplase 0.6 mg/kg body weight, up to a maximum dose of 50 mg, administered intravenously over 15 minutes.

  • Full-Dose AlteplaseMár használt kezelés, összehasonlításként

    Participants randomized to standard full-dose systemic thrombolysis will receive alteplase 1.5 mg/kg body weight, up to a maximum dose of 100 mg, administered as a 10 mg intravenous bolus over 1 to 2 minutes followed by a 90 mg intravenous infusion over 2 hours.

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on és az EU hivatalos vizsgálati nyilvántartásában (CTIS).
Hivatalos cím
Reduced-Dose Versus Full-Dose Systemic Thrombolysis for High-Risk Pulmonary Embolism: A Multicentre, Randomised, Open-Label, Blinded-Endpoint Trial
A regiszteradat frissítve
2026. október 28.